We are on Twitter now! follow us on Alembic Pharmaceuticals.

Alembic Pharmaceuticals receives USFDA Tentative Approval for Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials.

Alembic Pharmaceuticals announces USFDA Final Approval for Asenapine Sublingual Tablets, 5 mg and 10 mg.

Alembic Pharmaceuticals announces its wholly-owned subsidiary, Alembic Global Holding SA receives USFDA Final Approval for Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials.

Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation).

Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram.

Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receivesUSFDA Tentative Approval for Efinaconazole Topical Solution, 10%.